Compositions comprising estolide compounds and methods of making and using the same

US10240025B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10240025-B2
Application numberUS-201715831916-A
CountryUS
Kind codeB2
Filing dateDec 5, 2017
Priority dateJun 17, 2011
Publication dateMar 26, 2019
Grant dateMar 26, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are compositions comprising at least one estolide compound of formula: in which n is an integer equal to or greater than 0; m is an integer equal to or greater than 1; R 1 , independently for each occurrence, is selected from optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; R 2 is selected from hydrogen and optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; and R 3 and R 4 , independently for each occurrence, are selected from optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched. Also provided are uses of the compositions described herein.

First claim

Opening claim text (preview).

The invention claimed is: 1. A purified, optically active form of a compound of Formula I: wherein x is, independently for each occurrence, an integer selected from 2 to 8; y is, independently for each occurrence, an integer selected from 2 to 8; n is 0; R 1 is an unsubstituted C 1 -C 20 alkyl that is saturated or unsaturated, and branched or unbranched; and R 2 is hydrogen, wherein each fatty acid chain residue of the compound is unsubstituted. 2. The compound of claim 1 , wherein x is 3. 3. The compound of claim 2 , wherein y is 12. 4. The compound of claim 1 , wherein x is 7. 5. The compound of claim 4 , wherein y is 8. 6. The compound of claim 5 , wherein R 1 is an unsubstituted C 13 -C 17 alkyl. 7. The compound of claim 6 , wherein R 1 is saturated. 8. The compound of claim 7 , wherein R 1 is unbranched. 9. The compound of claim 5 , wherein R 1 is an unsubstituted C 15 alkyl that is unbranched. 10. The compound of claim 9 , wherein R 1 is saturated. 11. A composition comprising the compound of claim 10 and at least one additive. 12. The compound of claim 1 , wherein the compound is enantiomerically pure. 13. A composition comprising at least one optically-active estolide compound of Formula I: wherein x is, independently for each occurrence, an integer selected from 2 to 8; y is, independently for each occurrence, an integer selected from 2 to 8; n is 0; R 1 is an unsubstituted C 1 -C 20 alkyl that is saturated or unsaturated, and branched or unbranched; and R 2 is hydrogen, wherein each fatty acid chain residue of the compound is unsubstituted; and at least one additive. 14. The composition of claim 13 , wherein the at least one additive is selected from an antioxidant, a surfactant, and a stability enhancer. 15. A composition comprising at least one compound of claim 1 , and at least one additive. 16. The composition of claim 15 , wherein the at least one additive selected from an antioxidant, a surfactant, or a stability enhancer. 17. A composition comprising at least one compound of claim 6 , and at least one additive. 18. The composition of claim 17 , wherein the at least one additive selected from an antioxidant, a surfactant, or a stability enhancer. 19. A method comprising: providing first estolide compound of Formula I: wherein x is, independently for each occurrence, an integer selected from 2 to 8; y is, independently for each occurrence, an integer selected from 2 to 8; n is 0; R 1 is an unsubstituted C 1 -C 20 alkyl that is saturated or unsaturated, and branched or unbranched; and R 2 is hydrogen, wherein each fatty acid chain residue of the compound is unsubstituted; and resolving the first estolide compound to provide a second estolide compound having optical activity. 20. The method of claim 19 , wherein the first estolide compound comprises a racemate. 21. The method of claim 20 , wherein the second estolide compound is enantiomerically pure. 22. The method of claim 20 , wherein resolving the first estolide compound comprises the use of chiral chromatography. 23. The composition of claim 11 , wherein the at least one additive selected from an antioxidant, a surfactant, or a stability enhancer.

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10240025B2 cover?
Provided herein are compositions comprising at least one estolide compound of formula: in which n is an integer equal to or greater than 0; m is an integer equal to or greater than 1; R 1 , independently for each occurrence, is selected from optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; R 2 is selected from hydrogen and op…
Who is the assignee on this patent?
Biosynthetic Technologies Llc
What technology area does this patent fall under?
Primary CPC classification C08K5/11. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).